Pfizer's Duavee, a new estrogen-based drug for managing hot flashes caused by menopause, is due to hit at least some pharmacy shelves February 3.
According to Pfizer's website, about half of all post-menopausal women experience hot flashes. That's a potential market of 15 million. However, time will tell if women are willing to start or return to estrogen-based therapies for relief.
The FDA approved Duavee for moderate-to-severe vasomotor symptoms on October 23, 2013.